• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Sodium alginate as a novel therapeutic option in experimental colitis

    Author
    Mirshafiey, Abbas
    Khodadadi, Ali
    Rehm, Bernd H.A.
    Khorramizadeh, M. Reza
    Eslami, Mohammad Bagher
    Razavi, Alireza
    Saadat, Farshid
    Year published
    2005
    Metadata
    Show full item record
    Abstract
    The potential therapeutic effect of low‐viscosity sodium alginate (LVA) was studied in a rat model of acute colitis induced by intracolonic administration of acetic acid. This experimental model produced a significant ulcerative colitis. Induction of colitis also significantly enhanced the serum and colonic mucosal cytokine (IL‐6 and TNF‐α) and eicosanoid (LTB4 and PGE2) levels, which paralleled with the severity of colitis. LVA solution was administered orally as drinking water at concentration of 0.5% (W/V) for 1 week. The tolerability and inhibitory effect of LVA on matrix metalloproteinase‐2 (MMP‐2) were tested using WEHI‐164 cell line and zymography method. The results showed that LVA therapy is able to significantly reduce colonic damage score, histological lesion, serum and colonic mucosal IL‐6, TNF‐α, LTB4 and PGE2 levels in treated group compared with nontreated controls. Moreover, in vitro examinations revealed that treatment with LVA could diminish MMP‐2 activity. It is concluded that LVA is able to suppress acetic acid‐induced colitis in rats. Some of the action of LVA may be associated with its inhibitory effects on cytokine and eicosanoid production and MMP‐2 activity. Our data suggest that LVA could potentially be a novel therapeutic option for inflammatory bowel disease.
    Journal Title
    Scandinavian Journal of Immunology
    Volume
    61
    Issue
    4
    DOI
    https://doi.org/10.1111/j.1365-3083.2005.01571.x
    Subject
    Immunology not elsewhere classified
    Publication URI
    http://hdl.handle.net/10072/371549
    Collection
    • Journal articles

    Footer

    Social media

    • Facebook
    • Twitter
    • YouTube
    • Instagram
    • Linkedin
    First peoples of Australia
    • Aboriginal
    • Torres Strait Islander

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane
    • Australia